A Deeper Look at the Investigation
Investors in Ovid Therapeutics Inc. (NASDAQ: OVID) have been presented with a lens to examine the company’s inner workings. The Schall Law Firm has embarked on a quest to uncover potential violations of securities laws by Ovid.
The Allegations Unveiled
Diving into the heart of the matter, the investigation seeks to determine whether Ovid misled investors. This scrutiny follows Ovid’s announcement on March 30, 2021, regarding Takeda Pharmaceutical Company Limited’s acquisition of global rights to develop and commercialize soticlestat (TAK-935/OV935). Ovid later disclosed on June 17, 2024, that Takeda’s studies in Dravet syndrome and Lennox-Gastaut syndrome fell short of their primary endpoints.
Opportunity for Shareholders
For shareholders who bore the brunt of losses, an avenue has been paved for participation in this investigation. By engaging with the Schall Law Firm, shareholders can shed light on their experiences and learn about their rights, pro bono.
Contact and Counsel
To embark on this investigative journey, interested parties can reach out to Brian Schall at the Schall Law Firm’s offices in Los Angeles. Contact can also be established through their website or email, affording shareholders an opportunity to contribute their voices to the investigation.
A Closer Examination
With a global presence, the Schall Law Firm specializes in representing investors in securities class action lawsuits. As the investigation unfolds, this spotlight on Ovid Therapeutics Inc. provides investors with an informed perspective on the company’s operations.
Final Thoughts
In various jurisdictions, this press release may qualify as Attorney Advertising, adhering to the law and ethical standards. For those intrigued by the inner workings of market dynamics and legal intricacies, this investigation offers a front-row seat to investor advocacy.
